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Background: Salmonella is often associated with gastrointestinal disease outbreaks in humans throughout the
world due to the consumption of contaminated food. Our previous studies have shown that deletion of
glucose-inhibited division gene (gidA) significantly attenuated Salmonella enterica serovar Typhimurium (STM)
virulence in both in vitro and in vivo models of infection. Most importantly, immunization with the gidA mutant
protected mice from a lethal dose challenge of wild-type STM. In this study, we further characterize the gidA
mutant STM strain for potential use in a live-attenuated vaccine.
Results: The protective efficacy of immunization with the gidA mutant was evaluated by challenging immunized
mice with a lethal dose of wild-type STM. Sera levels of IgG2a and IgG1, passive transfer of sera and cells, and
cytokine profiling were performed to study the induction of humoral and cellular immune responses induced by
immunization with the gidA mutant strain. Additionally, a lymphocyte proliferation assay was performed to gauge
the splenocyte survival in response to treatment with STM cell lysate. Mice immunized with the gidA mutant strain
were fully protected from a lethal dose challenge of wild-type STM. Naïve mice receiving either cells or sera from
immunized mice were partially protected from a lethal dose challenge of wild-type STM. The lymphocyte
proliferation assay displayed a significant response of splenocytes from immunized mice when compared to
splenocytes from non-immunized control mice. Furthermore, the immunized mice displayed significantly higher
levels of IgG1 and IgG2a with a marked increase in IgG1. Additionally, immunization with the gidA mutant strain
evoked higher levels of IL-2, IFN-γ, and IL-10 cytokines in splenocytes induced with STM cell lysate.
Conclusions: Together, the results demonstrate that immunization with the gidA mutant strain protects mice by
inducing humoral and cellular immune responses with the humoral immune response potentially being the main
mechanism of protection.
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Salmonella is an enteric pathogen causing major pub-
lic health problems throughout the world due to
the consumption of contaminated food. Nontyphoidal
Salmonella species, like Salmonella enterica serovar
Typhimurium (STM), are the leading cause of hospital-
ization and death among the major foodborne pathogens
[1]. Antibiotic resistance by Salmonella is dramatically* Correspondence: fadl@wisc.edu
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distribution, and reproduction in any mediumincreasing, so the development of an effective vaccine
remains a global health priority [2,3].
Creating a safe and immunogenic vaccine strain is the
biggest challenge in developing an effective live-
attenuated Salmonella vaccine [4]. Several Salmonella
vaccines, including whole-cell killed and live vaccines,
have been developed with variable success [5,6]. These
vaccines either required repeated administration or
induced insufficient immune responses for long-lasting
protection against lethal challenges with virulence
Salmonella strains [7]. Many Salmonella vaccine strains
carry deletion mutations affecting metabolic functions
or virulence factors [8]. Several mutant strains oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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velop optimal immune responses [9-11]. Our approach
in constructing a live-attenuated Salmonella vaccine
strain is to create a mutant defective in tRNA modifica-
tion [12]. This strategy enables our vaccine strain to
express multiple virulence factors at a significantly
reduced level in order to obtain a safe and immuno-
genic vaccine candidate.
Glucose-inhibited division (GidA) protein (also known
as MnmG) was first described in Escherichia coli, where
deletion of gidA resulted in a filamentous morphology
when grown in a rich medium supplemented with glu-
cose [13]. Further studies showed GidA is a flavin di-
nucleotide (FAD) binding enzyme involved in the
fruiting body development of Myxococcus xanthus [14].
Furthermore, GidA has been shown to be a tRNA modi-
fication methylase in E. coli that forms a heterodimeric
complex with MnmE (also known as TrmE) to
catalyze the addition of a carboxymethylaminomethyl
(cmnm) group at the 5 position of the wobble uridine
(U34) of tRNAs [15-19]. Most importantly, deletion
of gidA has been shown to attenuate the pathogenesis
of some bacteria including Pseudomonas syringae,
Aeromonas hydrophila, Streptococcus pyogenes, and
Pseudomonas aeruginosa [20-23].
Our previous studies suggest a role for GidA in the
regulation of Salmonella virulence and cell division
[12,24]. In our initial study, the gidA mutant was attenu-
ated in vitro and showed a significant decrease in ability
to invade T84 intestinal epithelial cells as well as a sig-
nificant decrease in ability to replicate and produce cyto-
toxic affects on macrophages. Furthermore, global
transcriptional and proteomic profiling indicated a sig-
nificant down-regulation in numerous genes and pro-
teins involved in Salmonella pathogenesis [12]. Most
importantly, the gidA mutant was attenuated in mice as
shown by a significant increase in 50% lethal dose
(LD50), reduced systemic bacterial survival, defective in
the induction of inflammatory cytokines and chemo-
kines, and reduced severity of histopathological lesions
in the liver and spleen. Additionally, mice immunized
with the gidA mutant were protected from a lethal dose
challenge of wild-type (WT) STM [12].
In this study, we examined the relative contribution of
the humoral and cellular immune responses in the over-
all protective mechanism afforded by immunization with
the gidA mutant STM strain to further evaluate it as a
candidate for use in a live-attenuated vaccine. The pro-
tective efficacy of immunization with the gidA mutant
was evaluated by challenging immunized mice with a le-
thal dose of WT STM. Sera of control and immunized
mice were tested for levels of IgG1 and IgG2a to gauge
the Th1 and Th2 responses to gidA immunization. Add-
itionally, sera and cell culture supernatant were used todetermine the level of induction of Th1 (IL-2 and IFN-γ)
and Th2 (IL-4 and IL-10) cytokines in control and
immunized mice. Passive transfer studies were per-
formed to evaluate the role of humoral and cell
mediated immunity afforded by immunization with the
gidA mutant vaccine strain. A lymphocyte proliferation
assay was used to determine the ability of control and
immunized murine splenocytes to respond to treatment
with STM cell lysate. Taken together, these data indicate
the gidA mutant vaccine strain protects mice by indu-
cing humoral and cellular immune responses with the
humoral immune response being the primary mechan-
ism of protection.
Methods
Bacterial strains and growth conditions
The WT and gidA mutant Salmonella enterica serovar
Typhimurium (STM) 14028 strains are described in [12].
The organisms were grown in Luria-Bertani (LB) broth
and on LB agar plates in the presence of nalidixic acid
(150 μg/ml) or kanamycin (50 μg/ml). The bacteria were
cultivated at 37°C with shaking at 225 rpm. Bacteria
were harvested by centrifugation (5,000 rpm for 10 min),
washed twice with PBS, and resuspended in a minimal
amount of PBS.
Immunization of mice
Female BALB/c mice, 6–8 weeks old, were obtained
from Harlan Laboratories (Indianapolis, IN). All animal
procedures were approved by the University of
Wisconsin-Madison Animal Care and Use Committee.
Mice were kept under specific pathogen-free conditions
in filter-topped cages and provided with food and water
ad libitum. Mice were inoculated via the intraperitoneal
(i.p.) route with either 1 x 103 CFU of the gidA mutant
STM strain, or sterile PBS. The chosen time points for
the assays in this study are 7 and 42 days after
immunization. These time points were chosen to gauge
the immune response to the gidA mutant STM strain at
the early stage of infection and at the time of challenge.
At these time points, mice were sedated with isoflurane
(Abbott Laboratories, North Chicago, IL) and bled for
sera which were used to profile the Th1 and Th2 cyto-
kines, determine the IgG subclasses, and used in the
passive transfer experiment. The spleens were removed
and these cells were used for the cell population analysis,
lymphocyte proliferation assay, Th1 and Th2 cytokine
profiling, and the passive transfer experiment. At the
42 day time-point, selected mice that had been injected
with PBS and the gidA mutant STM strain were chal-
lenged with a lethal dose (1 x 105 CFU) of WT STM.
Morbidity and mortality of these animals were moni-
tored for 30 days after challenge. Mice suffering from
lethal salmonellosis as determined by severe hunched
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euthanized to prevent unnecessary suffering.
Splenic bacterial counts
The enumeration of bacteria from the spleen was per-
formed as previously described [12]. Briefly, spleen sam-
ples of 0.1 g were removed from mice inoculated with
sterile PBS or the gidA mutant STM strain, homoge-
nized in 1 ml PBS, and serial dilutions of the homogen-
ate were plated on Salmonella-Shigella (SS) and LB agar
plates. The plates were incubated at 37°C for 24 hours
and colonies were counted. Bacteria were enumerated
by determining the CFU in duplicate, and expressed as
CFU/ml.
Flow cytometric analysis
Spleens were removed from mice inoculated with sterile
PBS or the gidA mutant STM strain. The spleens were
homogenized in RPMI media supplemented with 2%
fetal bovine serum (FBS), filtered through a 70 μm
strainer, and the red blood cells were lysed with Pharm
Lyse cell lysis buffer (BD Bioscience, Franklin Lakes, NJ).
The spleen cells were washed twice with PBS sup-
plemented with 2% FBS, filtered through a 70 μm
strainer, and counted on a hemocytometer. Approxi-
mately 1 x 106 cells were placed in each tube, and incu-
bated with mouse CD16/CD32 monoclonal antibodies
(0.25 μg/100 μl) (BD Bioscience) for 15 min at room
temperature to block antibody binding to mouse Fc-γ
receptors. The cells were washed twice with PBS supple-
mented with 2% FBS and incubated with either anti-
CD4 antibody conjugated to PE-Cy5 (0.20 μg/100 μl) or
anti-CD8 antibody conjugated to PE-Cy7 (0.30 μg/100 μl)
and anti-CD44 antibody conjugated to fluorescein iso-
thiocyanate (FITC) (0.20 μg/100 μl) and anti-CD62L
antibody conjugated to phycoerythrin (PE) (0.10 μg/
100 μl). After incubation, the cells were washed once
with PBS supplemented with 2% FBS and fixed with 1%
formaldehyde. Analysis was performed at the University
of Wisconsin-Madison Carbone Cancer Center Flow
Cytometry Laboratory using a LSRII flow cytometer and
FlowJo software (Tree Star Inc., Ashland, OR).
ELISA
Initially, a whole-cell Salmonella enzyme-linked im-
munosorbent assay (ELISA) was performed as previously
described [25]. The purpose of this experiment is to
assay the serum antibody specific for our gidA mutant
STM strain. Serum IgG1 and IgG2a from mice inocu-
lated with sterile PBS or the gidA mutant STM strain
was measured 7 and 42 days post-immunization by
ELISA as previously described [10]. High-binding flat-
bottom ELISA plates (Thermo Fisher Scientific, Roches-
ter, NY) were coated with 1 μg/ml of capture antibody(anti-IgG1 or anti-IgG2a) (Bethyl Laboratories Inc.,
Montgomery, TX) diluted in 0.05 M carbonate/bicarbon-
ate buffer (pH 9.6) for 1 hour at room temperature. The
wells of the microtiter plate were washed five times with
washing buffer (50 mM Tris, 0.14 M NaCl, and 0.05%
Tween 20) and blocked with blocking buffer (50 mM
Tris, 0.14 M NaCl, and 1% bovine serum albumin
[BSA]) overnight at 4°C. After washing, sera from both
groups of mice were diluted in sample buffer (50 mM
Tris, 0.14 M NaCl, 1% BSA, and 0.05% Tween 20) and
the Mouse Reference Serum (Bethyl Laboratories Inc.)
was diluted two-fold starting at a concentration of
1000 ng/ml and used for plotting the standard curve.
After one hour incubation at room temperature, the
plates were washed five times with washing buffer, and
incubated for an additional hour at room temperature
after the addition of a 1:250,000 dilution of horserad-
ish peroxidase (HRP)-conjugated goat anti-mouse IgG
(Bethyl Inc.) to the wells of the microtiter plate. After
washing five times, 3, 3’, 5, 5’ tetramethylbenzidine
(TMB) substrate was added to visualize antigen-antibody
reactions. The reaction was stopped with 0.18 M H2SO4,
and the optical density was measured at 450 nm.
Lymphocyte proliferation assay
The lymphocyte proliferation assay was performed using
the described method [26]. Splenocytes harvested on day
7 and 42 post-immunization were used in the lympho-
cyte proliferation assay. After harvesting, live splenocytes
were determined by the trypan blue exclusion technique
and counting with a hemocytometer. Cells from both
groups of mice were plated in a 96-well U-bottom
microtiter plate (Corning Inc., Corning, NY) at a cell
density of 2 x 105 cells/well. The cells were treated with
STM cell lysate (1 μg/ml) and incubated at 37°C with 5%
CO2 for 48 hours. The STM cell lysate was created from
a WT STM 14028 culture that was grown to an optical
density (O.D.)600 of 1.0, washed twice with PBS, lysed by
sonication, and quantitated using a Bradford Assay. The
percentage of cell survival was determined using the
CytoTox-Glo Cytotoxicity Assay (Promega, Madison,
WI). Quantification of viable cells was determined by
the formula: Signal from Viable Cells = Total Cytotox-
icity Signal – Initial Cytotoxicity Signal.
Cytokine profiling
The cytokine profiling was performed using a commer-
cially based multiplex assay as described [12]. Th1 (IL-2
and IFN-γ) and Th2 (IL-4 and IL-10) cytokine levels
were determined from mouse sera at day 7 and 42 using
a multiplex assay (Quansys Biosciences, Logan, UT).
Cytokine production from splenocytes at day 7 and 42
was measured by plating splenocytes from both groups
of mice in a microtiter plate at a cell density of 2 x 105


















Figure 1 Percent survival of mice immunized by i.p. injection
with sterile PBS or 1 x 103 CFU of the gidA mutant vaccine
strain, and subsequently challenged with a lethal dose (1 x 105
CFU) of WT STM on day 42 post-immunization. Morbidity and
mortality of these animals were monitored for 30 days after
challenge. Full protection was provided to immunized mice while
100% mortality was seen in the control mice.















Figure 2 Determination of bacterial counts in the spleen of
mice immunized with 1 x 103 CFU of the gidA mutant vaccine
strain. Aliquots (0.1 g) of spleen were homogenized, serially diluted,
and plated out on SS and LB agar to determine bacterial counts.
The P value of 0.0014 shows a significant decrease in bacteria on
day 42 post-immunization when compared to day 7 post-
immunization. No bacteria were recovered from the spleens of the
control mice.
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(1 μg/ml) and incubated at 37°C with 5% CO2 for 48 hours.
The levels of Th1 and Th2 cytokines in the culture
supernatant were determined using a multiplex assay
(Quansys Biosciences).
Passive transfer of cells and sera
Mice were bled for sera and splenocytes were harvested
on day 42 post-immunization. Fifteen naïve mice were
used with the mice being divided into three groups with
five mice per group. Each group was inoculated via
retro-orbital injection [27] with either 100 μl sterile PBS,
100 μl of sera from non-infected mice, or 100 μl of sera
from mice immunized with the gidA mutant STM strain
[28]. Another fifteen naïve mice were divided into three
groups of five and each group was inoculated via retro-
orbital injection [27] with 100 μl sterile PBS, 100 μl of
splenocytes (1 x 107 cells/100 μl) from non-infected
mice, or 100 μl of splenocytes (1 x 107 cells/100 μl) from
mice immunized with the gidA mutant STM strain [28].
All groups were challenged by i.p. injection 24 hours
later with a lethal dose (1 x 105 CFU) of WT STM. Mor-
bidity and mortality of these animals were monitored for
30 days after challenge. Mice suffering from lethal sal-
monellosis as determined by severe hunched posture,
labored breathing, apathy, and ruffled fur were eutha-
nized to prevent unnecessary suffering.
Statistical analysis
Wherever appropriate, the data were analyzed using
GraphPad Prism 5 software (GraphPad Software, San
Diego, CA) and a Student’s t test. P values of ≤ 0.05 were
considered significant, and data were expressed as arith-
metic means with standard deviations. Animal mortality
was analyzed using the Kaplan-Meier survival analysis
with the log-rank (Mantel-Cox) significance test.
Results
Protective efficacy of the gidA mutant STM strain
To examine the protection provided by GidA immu-
nization, six BALB/c mice were i.p. injected with sterile
PBS while another six mice were injected with 1 x 103
CFU of the gidA mutant STM strain. AT 42 days post-
immunization, all twelve mice were challenged with a
lethal dose (1 x 105 CFU) of WT STM. All of the
control mice challenged with the WT STM strain died
within four days of challenge. Meanwhile, all of the
mice immunized with the gidA mutant STM strain
survived the lethal dose challenge of WT STM. Fur-
thermore, none of the mice immunized with the gidA
mutant STM strain showed any lack of mobility,
hunched posture, or ruffled fur associated with septic
shock (Figure 1).Splenic bacterial counts after immunization
We previously reported the level of bacteria recovered
from spleens of mice inoculated with the gidA mutant
STM strain was significantly less than that recovered
from spleens of mice inoculated with the WT STM
strain [12]. In this study, the in vivo stability of the gidA
mutant STM strain was determined by examining its
ability to colonize the spleen at Day 7 and at the time of
challenge (Day 42). The number of viable bacteria recov-
ered from mice immunized with the gidA mutant STM
strain was 4.0 logs on day 7 post-immunization. At day
42 post-immunization, viable bacteria were still recov-
ered from the spleen at 0.9 logs (Figure 2). The long per-
sistence of the bacteria in mouse splenic tissues could
A.
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Figure 3 BALB/c mice were immunized with 1 x 103 CFU of the
gidA mutant vaccine strain or sterile PBS. Serum IgG2a (A) and
serum IgG1 (B) concentrations were determined by ELISA at the
indicated times after immunization. The actual P values are provided
comparing the sera levels of the immunized mice to that of the
control group.
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immunized with the gidA mutant STM strain. As shown
by the histopathological grading in our initial GidA
study, the colonization of the gidA mutant STM strain
only caused mild necrosis with moderate infiltration of
inflammatory cells in the spleen with little to no induc-
tion of proinflammatory cytokines and chemokines [12].
T cell analysis in mice immunized with the gidA mutant
STM strain
To determine whether T cells were activated in BALB/c
mice immunized with 1 x 103 CFU of the gidA mutant
STM strain, isolated splenocytes from control and
immunized mice were harvested at day 7 and 42 post-
immunization. Splenocytes from both groups of mice
were stained with antibodies against CD4 or CD8 in
combination with anti-CD44 and anti-CD62L antibodies.
These markers are used to distinguish naïve from acti-
vated or memory T cells [29]. The level of CD4+ cells
were higher in the immunized mice (21.3%) when com-
pared to the control mice (16.1%) on day 7 and again on
day 42 (28.1 and 23.5%, respectively). There was no dif-
ference in the CD8+ populations between the control
and immunized mice on day 7 and 42. Furthermore, on
day 7 and 42 post-immunization, there was no signifi-
cant difference between the control and gidA mutant
immunized mice in the percentage of CD44+ and
CD62L+ in both CD4+ and CD8+ T cells (data not
shown).
Serum IgG levels in mice after immunization
The Salmonella whole cell ELISA displayed a high-level
of Salmonella specific antibody. In order to further
characterize the immune response elicited after
immunization with the gidA mutant STM strain, the
sera of control and immunized mice were examined for
the production of IgG2a and IgG1 antibodies as markers
of Th1 and Th2 subsets, respectively. These findings
indicate a significant increase in both IgG2a [P=0.0317
and P= 0.0179 for GidA day 7 and 42, respectively,
compared to the control] and IgG1 [P=0.0051 and
P =0.0007] in the sera of mice immunized with the
gidA mutant STM strain with the highest levels being
assayed on day 42 post-immunization. Furthermore,
the IgG1 response, indicative of Th2, was higher in
the immunized mice than the IgG2a response level
in the immunized mice (Figure 3).
Lymphocyte proliferation assay
Splenocytes harvested from control mice and mice
immunized with the gidA mutant strain were used to
examine the cellular immune response against treatment
with STM cell lysate. At day 7 post-immunization, the
splenocytes from the immunized mice displayed asignificant proliferative response (932,590) [P=0.0113]
compared to the splenocytes from the control mice
(365,910). Once again, at 42 days post-immunization,
the splenocytes from the immunized mice showed a
significantly higher proliferative response (411,177)
[P=0.0282] than the splenocytes from control mice
(81,574) when treated with STM cell lysate. In con-
trast, splenocytes from non-immunized control mice
showed little proliferation in response to treatment
with the STM cell lysate (Figure 4).
Cytokine analysis
Sera and splenocyte cell culture supernatants were
examined for both Th1 (IL-2 and IFN-γ) and Th2 cyto-
kines (IL-4 and IL-10). The sera of mice immunized with
the gidA mutant STM strain showed no difference from
that of the control sera in the level of cytokine induction
on days 7 and 42 post-immunization (data not shown).
These data confirm the findings in our initial GidA
study which showed a marked reduction in the levels of
all of the major cytokines when compared to sera of
















Figure 4 Lymphocyte proliferation assay displaying the survival
of splenocytes from control and immunized mice before and
after treatment with STM cell lysate. The actual P values for the
given time points are provided showing the significant increase in
proliferation in splenocytes from immunized mice in comparison to
splenocytes from control mice.
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Figure 5 Induction of IL-2, IFN-γ, and IL-10 in the cell culture
supernatant from control and immunized mice before and
after treatment with STM cell lysate. Splenocytes were collected
from both groups of mice at days 7 and 42 post-immunization and
the levels of IL-2 (A), IFN-γ (B), and IL-10 (C) was determined using a
multiplex assay. The actual P values are given for each time point.
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culture supernatant, the induction of Th1 and Th2 cyto-
kines were significantly increased when GidA spleno-
cytes were induced with STM cell lysate. Meanwhile,
there was little to no cytokine induction in the cell cul-
ture supernatant when splenocytes from control mice
were treated with the STM cell lysate. Furthermore,
there was no IL-4 induction in either the control or
GidA groups at days 7 and 42 (data not shown). On days
7 and 42 post-immunization, there was no difference
between the treated and untreated control groups in
the level of IL-2 induction. The level of IL-2 induction,
however, significantly increased in the GidA treated
cells (Figure 5A) [P=0.0007 and P <0.0001]. The level
of IFN-γ displayed a slight increase in the control trea-
ted cells (11.8 pg/ml) over the untreated control cells
(0.3 pg/ml) on day 7, but showed no difference on day
42. In contrast, the GidA treated cells showed a marked
increase in IFN-γ induction (1388.4 and 108.2 pg/ml)
[P <0.0001 and P=0.0001] compared to the untreated
GidA cells (0.3 and 0.3 pg/ml) on days 7 and 42, re-
spectively (Figure 5B). The levels of IL-10 were similar
between the control groups on day 7, but the level of
IL-10 induction in the GidA treated cells were signifi-
cantly higher than that of the GidA untreated cells
[P=0.0001]. On day 42, there was no difference in
IL-10 induction in either the control or GidA group
(Figure 5C). Together, these results indicate that immuni-
zation with the gidA mutant STM strain elicited a mixed
Th1 and Th2 response when treated with STM cell lysate.
Protective efficacy of cells and sera
A passive-immunization study was performed in order
to evaluate the roles of antibody and cell mediated im-
munity provided by immunization of mice with the gidA
mutant STM strain. Spleen lymphocytes (1 x 107 cells/100 μl) or 100 μl of pooled sera taken from immunized
mice or controls was administered by retro-orbital injec-
tion into groups of five naïve mice. Another group of
five naïve mice was injected with sterile PBS to serve as
an additional control. Approximately 24 hours later, all
mice were challenged with a lethal dose (1 x 105 CFU)
of the WT STM strain. All of the mice receiving control
sera, control cells, or sterile PBS died within four days of
being challenged by the WT STM strain. The sera trans-
ferred from the gidA mutant immunized mice protected
three of the five naïve mice from challenge. Further-
more, the two mice in this group that died showed a
delay in death (7 and 8 days following challenge) when
compared to the control serum and PBS control groups
(Figure 6A). The cells transferred from the gidA mutant
immunized mice protected two of the five naïve mice
from challenge. The three mice that died from this
group died in the same time period as mice receiving
control cells and PBS (Figure 6B). From these data both
parts of the immune response are somewhat protective,
A.







































Figure 6 Mice were immunized with 1 x 103 CFU of the gidA mutant vaccine strain or sterile PBS. Serum and cells were collected
42 days later and transferred to groups of five naïve mice. All recipient mice were challenge by i.p. injection with 1 x 105 CFU of WT STM
24 hours after transfer. Morbidity and mortality of these animals were monitored for 30 days after challenge. The serum passive transfer (A) was
statistically significant with a P value of 0.0414 while the cell passive transfer (B) was not statistically significant. Statistical significance was
calculated using the Kaplan-Meier survival analysis with the log-rank (Mantel-Cox) significance test.
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crucial of the two in protecting mice from WT STM.
Discussion
In this study, for the first time, the mechanism of
protection provided by immunization with the gidA
mutant STM strain was characterized. GidA was ori-
ginally thought to be involved in cell division due to
the filamentous morphology observed when the cells
were grown in rich medium supplemented with glu-
cose [13]. More recent studies done in E. coli have
shown GidA modulates several bacterial factors by a
post-transcriptional mechanism to modify tRNA by the
addition of a cmnm group at the 5 position of the wob-
ble uridine (U34) of tRNAs [15-19,30,31]. It has been
proposed that tRNA modification can serve as a regula-
tory mechanism to modulate gene expression[32]. Fur-
thermore, it has been suggested that secreted proteins
are particularly vulnerable to U34 hypomodification, and
many codons in bacteria require proper U34 modifica-
tion for efficient decoding [33]. Studies will need to be
conducted in Salmonella to see if GidA modifies tRNAin the same fashion as in E. coli. Such studies are cur-
rently underway in this laboratory.
Immunization of mice with the gidA STM mutant
strain provided full protection from a lethal dose chal-
lenge of WT STM. All of the immunized mice survived
a lethal dose challenge, while all the naïve mice died
within 4 days of challenge. Furthermore, none of the
immunized mice displayed any visual signs of illness or
septic shock associated with Salmonella infection. We
chose to challenge the immunized mice with a WT STM
dose of 1 x 105 CFU which is highly lethal. In our initial
GidA study, this dose was approximately 1000 times
higher than the LD50 of the WT STM strain [12]. We
chose such a high challenge dose because we feel it is
more reflective of the amount of Salmonella animals are
exposed to in the environment.
Antibody responses are known to contribute to Sal-
monella immunity [34-36]. It has been proposed that
antibodies made by IgM memory B cells are the first-
line defense mechanism against all infections and these
antibodies are the only defense against T cell-
independent antigens [37]. Studies in B cell deficient
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protection from both primary and secondary Salmonella
infection [36]. Our data indicates a strong humoral re-
sponse to immunization with the gidA mutant STM
strain. The Th2 marker, IgG1, showed a marked increase
in sera of mice immunized with the gidA mutant STM
strain. Naïve mice receiving sera from immunized mice
were more protected than naïve mice receiving a passive
transfer of cells from immunized mice. Further, the level
of the Th2 cytokine IL-10 showed a significant increase
in induction when splenocytes from immunized mice
were treated with STM cell lysate. The strong Th2 re-
sponse, however, was not accompanied by an increase in
IL-4 induction. IL-4, along with IL-10, induces differen-
tiation of uncommitted T cells toward a Th2 phenotype
[38,39]. One possible explanation for this could be rea-
soned from the study by Okahashi et al. In their study,
IL-4 knockout mice which were unable to generate
classical Th2-type responses were still capable of pro-
ducing significant antibody responses to inoculation
with Salmonella [40].
Since Salmonella is a facultative intracellular pathogen,
cellular immune responses are considered to be a crucial
component of protective immunity. Protective cellular
mediated immunity is mediated by CD4+ cells which
results in the activation of macrophages and delayed-
type hypersensitivity responses. Numerous gene target
studies have shown the importance of CD4+ activation
in resistance to Salmonella infection [41,42]. Our data
indicates a cellular immune response in mice immunized
with the gidA mutant STM strain. Although the flow
cytometric analysis showed no induction of memory T
cells, or difference in CD8+ cells, it shows an increase in
CD4+ population in the immunized mice at both day 7
and 42 post-immunization. It has been shown that CD4+
cells are more important than CD8+ in resistance to
Salmonella infection [43,44]. The passive transfer of cells
to naïve mice from immunized mice did not confer full
protection, and was not as significant as the serum pas-
sive transfer, but there was enough cell mediated im-
munity activated to protect a portion of the mice from a
lethal dose challenge. Furthermore, splenocytes from
immunized mice proliferated at a much higher rate than
splenocytes from control mice when treated with STM
cell lysate. The IgG1 induction was significantly more
prominent than the induction of IgG2a, but the level of
IgG2a was still significantly higher in the immunized
mice than in that of the sera of the control mice. Fur-
thermore, the induction of the Th1 cytokines, IL-2 and
IFN-γ, shows a strong indication of cell mediated im-
munity induced by immunization. In particular, IFN-γ
showed a marked increase in cell culture supernatant
when splenocytes from immunized mice were treated
with STM cell lysate.The general consensus is that the ideal Salmonella vac-
cine should generate both humoral and cell mediated im-
munity. This is due to protective immunity to Salmonella
in mice being attributed to a balance between humoral
and cell mediated immunity with an emphasis on develop-
ment of the Th1 and Th2 subsets [45,46]. In this study,
the gidA mutant vaccine strain generated both Th1 and
Th2 immunity with the Th2 immune response being the
more prominent of the two. This was somewhat sur-
prising since Salmonella is a facultative intracellular
pathogen. One possible explanation for this could be
found in our initial GidA study comparing the gidA
mutant to the WT STM strain. The gidA mutant showed
an approximate 1000-fold reduction in the ability to in-
vade T84 intestinal epithelial cells, as well as a marked re-
duction in ability to cause systemic infection in mice.
Additionally, transcriptional and proteomic profiling iden-
tified a significant down-regulation in numerous genes
and proteins responsible for invasion. Overall, the gidA
mutant vaccine strain provides full protection to mice
when challenged with a highly lethal dose of WT STM.
The passive transfer experiments show the importance of
both humoral and cell mediated immunity in this
protective mechanism. This is an initial study in
which a proof of principle of protective immunity has
been established suggesting a gidA mutant STM strain
could be a good candidate for use in a live-attenuated
Salmonella vaccine. Future studies will be conducted
using oral immunization in order to establish the optimal
immunization route. Once the immunization route is
established, further studies will be conducted in a target
host animal to determine efficacy and long-term protec-
tion. Based on our initial data, we believe a gidA mutant
STM strain used in a live-attenuated vaccine could
provide superior protection against highly lethal levels of
Salmonella by stimulating humoral, cellular immunity and
potentially mucosal immunity.
Conclusions
Immunization with the gidA mutant STM strain pro-
vided full protection from a lethal dose challenge of WT
STM. Sera levels of IgG2a and IgG1 were significantly
higher in immunized mice when compared to sera of
control mice, and the level of IgG1 showed a marked in-
crease over IgG2a in the sera of immunized mice. Naïve
mice receiving sera and cells from immunized mice were
only partially protected from a lethal dose challenge of
WT STM with the sera being more protective than the
cells. A lymphocyte proliferation assay showed a marked
response of splenocytes from immunized mice to treat-
ment with STM cell lysate. Furthermore, the Th1 (IL-2
and IFN-γ) and Th2 (IL-10) cytokines showed a signifi-
cant increase in the cell culture supernatant of spleno-
cytes of immunized mice when treated with STM cell
Shippy and Fadl BMC Microbiology 2012, 12:286 Page 9 of 10
http://www.biomedcentral.com/1471-2180/12/286lysate. These data indicated the gidA mutant vaccine
strain protects mice by inducing humoral and cellular
immune responses with the humoral immune response
being the primary mechanism of protection.
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